VivoSeq
Dermatology

Severe Burns

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Severe Burns is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

50/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Unknown status2 · 50%
Terminated2 · 50%

Clinical Trials

Trial Activity

Supernormal Oxygen Delivery for Patients With Severe Burns
Unknown status·—·Phase 1·NCT05241912·100 enrolled
Development of pk/pd Model of Propofol in Patients With Severe Burns
Terminated·VVictor Contreras, MSN·N/A·NCT03704285·15 enrolled
Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries
Terminated·LLaboratoires Genévrier·Phase 2·NCT00366041·20 enrolled
Organ Protective Effect of Cetirizine In Patients With Severe Burns
Unknown status·RRuijin Hospital·Phase 1/2·NCT06126991·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)